Endometrial Cancer

The addition of durvalumab to chemotherapy — either alone or in combination with olaparib — improved outcomes for women with advanced endometrial cancer, according to the agent’s manufacturer.

A deep learning model accurately identified women with endometrial cancer at low and high risk for distant recurrence, according to research presented at American Association for Cancer Research Annual Meeting.

The Healio Editors compiled a list of recent news from the Society of Gynecologic Oncology Annual Meeting held from March 25-28, 2023.

Dostarlimab plus carboplatin significantly increased PFS among women with primary advanced or recurrent endometrial cancer, according to study results presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

The addition of pembrolizumab to chemotherapy significantly extended PFS for women with advanced or recurrent endometrial cancer, according to study results presented at Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.

The FDA granted regular approval to dostarlimab-gxly for treatment of certain women with endometrial cancer.

The addition of pembrolizumab to chemotherapy significantly extended PFS as first-line treatment for advanced or recurrent endometrial carcinoma, according to the agent’s manufacturer.

Tamoxifen use in the treatment of breast cancer was associated with greater risks for endometrial cancer, hyperplasia and polyps, as well as other uterine cancers among premenopausal women in Korea, according to study data.

A combination of dostarlimab-gxly and standard-of-care chemotherapy significantly extended PFS compared with placebo and chemotherapy among women with primary advanced or recurrent endometrial cancer, topline data showed.

A greater number of live births causally reduced the risk for endometrial cancer, according to study results published in BMC Medicine.